DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers

DAREON™ 5: DLL-3 BiTE for Neuroendocrine Cancers

IDENTIFIER (ClinicalTrials.gov): NCT05882058

DRUG/TREATMENT: BI 764532

PHASE: 2

STATUS: Recruiting

SPONSOR: Boehringer Ingelheim

DESCRIPTION:

Boehringer Ingelheim is sponsoring DAREON™-5, a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532.  

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Boehringer Ingelheim

EMAIL: clintriage.rdg@boehringer-ingelheim.com

PHONE: 1-800-243-0127